TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

被引：0
|
作者：
Julia Eckardt
Christopher Schroeder
Peter Martus
Sorin Armeanu-Ebinger
Olga Kelemen
Axel Gschwind
Irina Bonzheim
Thomas Eigentler
Teresa Amaral
Stephan Ossowski
Olaf Rieß
Lukas Flatz
Claus Garbe
Andrea Forschner
机构：
[1] University Hospital of Tübingen,Department of Dermatology
[2] University Hospital Tübingen,Institute for Clinical Epidemiology and Applied Biometrics
[3] University Hospital Tübingen,Institute of Medical Genetics and Applied Genomics
[4] University Hospital Tübingen,Institute of Pathology and Neuropathology
[5] Charité Berlin,Department of Dermatology
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Anti-PD-1; Adjuvant; Melanoma; Checkpoint inhibition; Tumor mutational burden; RFS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：833 / 840
页数：7
相关论文
共 50 条
  • [31] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
    Robert, Caroline
    Lebbe, Celeste
    Lesimple, Thierry
    Lundstrom, Eija
    Nicolas, Valerie
    Gavillet, Bruno
    Crompton, Philippa
    Baroudjian, Barouyr
    Routier, Emilie
    Lejeune, Ferdy J.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865
  • [32] BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy
    Barbour, Andrew P.
    Tang, Yue Hang
    Armour, Nicola
    Dutton-Regester, Ken
    Krause, Lutz
    Loffler, Kelly A.
    Lambie, Duncan
    Burmeister, Bryan
    Thomas, Janine
    Smithers, B. Mark
    Hayward, Nicholas K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (15) : 2668 - 2676
  • [33] Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma
    Gibney, Geoffrey Thomas
    Weber, Jeffrey S.
    Kudchadkar, Ragini Reiney
    De Conti, Ronald C.
    Tetteh, Leticia
    Eysmans, Cabell
    Yu, Bin
    Martinez, Alberto J.
    Younos, Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.
    Gibney, Geoffrey Thomas
    Tang, Shaojun
    Poorman, Kelsey
    Olszanski, Anthony J.
    Eisenberg, Burton Larry
    Mehmi, Inderjit
    Farma, Jeffrey M.
    In, Gino Kim
    Amin, Asim
    Rapisuwon, Suthee
    Vanderwalde, Ari M.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma
    Goodman, Rachel S.
    Justice, Joy
    Gardner, Laura J.
    Singh, Reena
    Dewan, Anna K.
    Johnson, Douglas B.
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [36] What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma
    Mooradian, Meghan J.
    Sullivan, Ryan J.
    ONCOLOGY-NEW YORK, 2019, 33 (04): : 141 - 148
  • [37] Impact of age on toxicity in patients treated with anti-PD-1 therapy for melanoma
    Shah, Kaustav P.
    Song, Haocan
    Ye, Fei
    Salem, Joe-Elie
    Balko, Justin
    Johnson, Douglas B.
    CANCER RESEARCH, 2020, 80 (16)
  • [38] Limited-duration anti-PD-1 therapy for patients with metastatic melanoma
    Makela, Siru
    Kohtamaki, Laura
    Laukka, Marjut
    Juteau, Susanna
    Hernberg, Micaela
    ACTA ONCOLOGICA, 2020, 59 (04) : 438 - 443
  • [39] Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
    Jacques, S. K.
    McKeown, J.
    Grover, P.
    Park, B.
    Zaremba, A.
    Dimitriou, F.
    Rashid, M. F. Harunal
    Namikawa, K.
    Mooradian, M.
    Placzke, J.
    Allayous, C.
    Mehmi, I.
    DePalo, D.
    Wicky, A.
    Schwarze, J. K.
    Nakamura, Y.
    Benannoune, N.
    Menzies, A. M.
    Lo, S. N.
    Carlino, M. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S915 - S916
  • [40] Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients
    Di Pietro, Francesca Romana
    Verkhovskaia, Sofia
    Falcone, Rosa
    Poti, Giulia
    Carbone, Maria Luigia
    Morelli, Maria Francesca
    Zappala, Albina Rita
    Morese, Roberto
    Di Rocco, Zorika Christiana
    Piesco, Gabriele
    Chesi, Paolo
    Failla, Cristina Maria
    Marchetti, Paolo
    De Galitiis, Federica
    FRONTIERS IN ONCOLOGY, 2024, 14
12345